Pharvaris N.V.
PHVS · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.91 | -0.13 | 0.43 | -0.13 |
| FCF Yield | -3.67% | -4.88% | -3.51% | -3.73% |
| EV / EBITDA | -15.34 | -13.19 | -16.02 | -15.69 |
| Quality | ||||
| ROIC | -21.92% | 18.78% | -17.41% | -12.84% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.82 | 0.66 | 0.84 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 22.44% | -10.02% | -4.61% | -21.08% |
| Safety | ||||
| Net Debt / EBITDA | 4.94 | 5.60 | 6.22 | 8.06 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -4,149.10 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |